Advertisement

Topics

Cerus Company Profile

01:12 EDT 21st September 2017 | BioPortfolio

At Cerus Corporation we have developed a platform technology (Helinx®) that prevents nucleic acid (DNA and RNA) replication. The Company's initial application of this technology is the development of the INTERCEPT Blood Systems to inactivate viruses, bacteria and other pathogens in the blood components used for transfusion - platelets, plasma and red blood cells.

Location

2411 Stanwell Drive
Concord
CA
94520
United States of America

Contact

Phone: (925) 288-6000
Fax: (925) 288-6001
Email: customer_services@cerus.com


News Articles [37 Associated News Articles listed on BioPortfolio]

Cerus exercises more options in BARDA contract

Cerus has exercised additional options with the Biomedical Advanced Research and Development Authority for studies of INTERCE -More- 

Cerus to Present at Cantor Fitzgerald’s Annual Healthcare Conference on September 27, 2017

Cerus Corporation (NASDAQ:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present a corporate update at the ...

EU approves neurovascular system from Cerus

European regulators have given Cerus Endovascular CE mark approval for its Contour neurovascular system, a device intended fo -More- 

Cerus to Present at Two Upcoming Conferences

Cerus Corporation (NASDAQ:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, will present at two upcoming conferences: ...

Cerus to Release Second Quarter 2017 Results on August 3, 2017

Cerus Corporation (NASDAQ:CERS) announced today that its second quarter results will be released on Thursday, August 3, 2017, after the close of the stock market. The company will...

Cerus Endovascular’s Contour Neurovascular System receives CE Mark approval for aneurysm treatment

Cerus Endovascular Ltd. today announced that it has received CE Mark approval for the commercial sale of its Contour Neurovascular System™ for the treatment of intra-cranial aneurysms (IAs) across t...

Cerus Exercises Additional BARDA Contract Options Totaling $46.6M

Cerus reported that additional options totaling $46.6M have been exercised under its contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of He...

Is Cerus's Intercept A Pick-6?

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Cerus

At Cerus Corporation we have developed a platform technology (Helinx®) that prevents nucleic acid (DNA and RNA) replication. The Company's initial application of this technology is the development o...

Cerus Corporation and SunCoast Blood Bank

Cerus Corporation

Condensed Consolidated Unaudited Balance Sheets

More Information about "Cerus" on BioPortfolio

We have published hundreds of Cerus news stories on BioPortfolio along with dozens of Cerus Clinical Trials and PubMed Articles about Cerus for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cerus Companies in our database. You can also find out about relevant Cerus Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Corporate Database Quicklinks



Searches Linking to this Company Record